RECRUITING

CORE-COMPARE Pilot Study

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The utility of Ultra High-Resolution Computed Tomography (UHR-CT) compared to conventional CT in all-comers (i.e., a generally lower-risk population) remains uncertain but is an important area of study in order to justify wider spread implementation and use of this technology, particularly in light of reports of significantly higher radiation exposure with UHR-CT, as well as longer scan times. The availability of technology to reconstruct conventional resolution (CR) simulation images from the raw CT acquisition data acquired on the UHR-CT scanner offers a unique platform to study this question without subjecting individuals to two different scans. The primary objective of this study is to generate preliminary data in support of the hypothesis that noninvasive UHR-CT is superior to conventional resolution CT for identifying patients with obstructive CHD.

Official Title

Ultra-High Resolution Computed Tomography (CT) vs. Conventional CT for Detecting Obstructive Coronary Artery Disease (CAD) The CORE-COMPARE Pilot Study

Quick Facts

Study Start:2021-04-05

Study Completion:2027-04-05

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06170541

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 85 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Patients aged 21-85 years * Clinical history suggestive of CHD who are referred by their primary cardiologist for further evaluation via Computed tomography angiography (CTA) will be asked to participate. * Women of child bearing potential must demonstrate a negative pregnancy test within 24 hours of the study CTA. * Ability to understand and willingness to sign the Informed Consent Form.	* Known allergy to iodinated contrast media. * History of multiple myeloma or previous organ transplantation * Elevated serum creatinine (\> 1.5mg/dl) OR calculated creatinine clearance of \< 60 ml/min (using the Cockcroft-Gault formula * Atrial fibrillation or uncontrolled tachyarrhythmia, or advanced atrioventricular block (second or third degree heart block) * Evidence of severe symptomatic heart failure (NYHA Class III or IV); * Known or suspected moderate or severe aortic stenosis * History of prior percutaneous coronary intervention (PCI) in one or more vessel or history of coronary arterial bypass grafting (CABG) * Suspected acute coronary syndrome * Presence of any other history or condition that the investigator feels would be problematic

Inclusion Criteria

Exclusion Criteria

* Patients aged 21-85 years
* Clinical history suggestive of CHD who are referred by their primary cardiologist for further evaluation via Computed tomography angiography (CTA) will be asked to participate.
* Women of child bearing potential must demonstrate a negative pregnancy test within 24 hours of the study CTA.
* Ability to understand and willingness to sign the Informed Consent Form.

* Known allergy to iodinated contrast media.
* History of multiple myeloma or previous organ transplantation
* Elevated serum creatinine (\> 1.5mg/dl) OR calculated creatinine clearance of \< 60 ml/min (using the Cockcroft-Gault formula
* Atrial fibrillation or uncontrolled tachyarrhythmia, or advanced atrioventricular block (second or third degree heart block)
* Evidence of severe symptomatic heart failure (NYHA Class III or IV);
* Known or suspected moderate or severe aortic stenosis
* History of prior percutaneous coronary intervention (PCI) in one or more vessel or history of coronary arterial bypass grafting (CABG)
* Suspected acute coronary syndrome
* Presence of any other history or condition that the investigator feels would be problematic

Contacts and Locations

Study Contact

Joao Lima, Professor

CONTACT

4106141284

jlima@jhmi.edu

Principal Investigator

Joao Lima, Professor

PRINCIPAL_INVESTIGATOR

Study Locations (Sites)

Johns Hopkins School of Medicine

Baltimore, Maryland, 21205

United States

Collaborators and Investigators

Sponsor: Johns Hopkins University

Joao Lima, Professor, PRINCIPAL_INVESTIGATOR, MD

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-04-05

Study Completion Date2027-04-05

Study Record Updates

Study Start Date2021-04-05

Study Completion Date2027-04-05

Terms related to this study

Additional Relevant MeSH Terms

Coronary Heart Disease (CHD)